Detalhe da pesquisa
1.
Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
Br J Haematol
; 204(3): 910-920, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38098188
2.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood
; 139(8): 1198-1207, 2022 02 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34469514
3.
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood
; 135(25): 2266-2270, 2020 06 18.
Artigo
Inglês
| MEDLINE | ID: mdl-32244251
4.
Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
Br J Haematol
; 2024 Mar 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38544472
5.
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Br J Haematol
; 202(4): 893-896, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37280781
6.
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blood
; 135(10): 773-777, 2020 03 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31951646
7.
Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing.
Haematologica
; 106(1): 313-315, 2021 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32817290
8.
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.
Br J Haematol
; 186(6): e188-e191, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31234236
9.
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
J Clin Oncol
; : JCO2301599, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38427924
10.
Persistence of UBTF tandem duplications in remission in acute myeloid leukaemia.
EJHaem
; 4(4): 1105-1109, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38024622
11.
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
Blood Adv
; 6(2): 503-508, 2022 01 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34861696
12.
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Cancer Discov
; 9(3): 342-353, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30514704